UBS
30 LinkedIn AdsTeam & Hiring
Employees
2
Open Roles
0
Unlock full report
Get the complete competitive intelligence dashboard with strategy analysis and weekly briefings.
Positioning
A/B Test
UBS United States of America
How will shifting world events impact your investments?
Mar 26 – May 26
UBS Financial Advisors Clarity in a rapidly changing world
May 26 – May 26
How will shifting world events impact your investments?
May 26 – May 26
Your wealth journey, your way.
May 26 – May 26
How will shifting world events impact your investments?
May 26 – May 26
UBS United States of America
May 26 – Jun 26
A/B Test
How will shifting world events impact your investments?
UBS United Kingdom
Jun 26 – Jul 26
America at 250: Innovation never ages
Jul 26 – Jul 26
UBS United States of America
Jul 26 – Jul 26
Global wealth continues its upward trajectory
Jul 26 – Jul 26
A/B Test
America at 250: Innovation never ages
UBS United States of America
Jul 26 – Sep 26
You’re moving at the speed of life
Sep 26 – Sep 26
UBS United States of America
Sep 26 – Sep 26
You’re moving at the speed of life
Sep 26 – Sep 26
UBS United States
Sep 26 – Oct 26
You’re moving at the speed of life
Oct 26 – Oct 26
04/2605/2606/2607/2608/2609/2610/26
A/B Test
UBS United States of America
How will shifting world events impact your investments?
UBS Financial Advisors Clarity in a rapidly changing world
How will shifting world events impact your investments?
Your wealth journey, your way.
How will shifting world events impact your investments?
UBS United States of America
A/B Test
How will shifting world events impact your investments?
UBS United Kingdom
America at 250: Innovation never ages
UBS United States of America
Global wealth continues its upward trajectory
A/B Test
America at 250: Innovation never ages
UBS United States of America
You’re moving at the speed of life
UBS United States of America
You’re moving at the speed of life
UBS United States
You’re moving at the speed of life
UBS
NewsUBS Maintains Buy on Lonza Amid Vaccine Upside
Lonza could generate up to $550 million in peak revenue from a Phase III pneumonia vaccine developed with Vaxcyte; UBS maintains a Buy with a CHF 685 target as Capital Markets Day nears; shares rose after positive trial results and supply‑chain confirmation.
UBS
SocialOxford–UBS Centre appoints Tsoukalas AI and Society Lead
Oxford–UBS Centre appoints Gerry Tsoukalas as Research Theme Lead for AI and Society; he is Oxford Saïd's Deputy Dean for Human-Centered AI and Innovation with finance, tech, academia, and AI governance experience, while UBS highlights trust and market implications.
UBS
Homepage1 page change detected
UBS
Follow-UpUBS Cuts Xylem Price Target Ahead of Results
UBS lowers Xylem price target to $112 from $138 as valuation concerns grow; Xylem issued a $1.5 billion senior bond to fund acquisitions.
Unlock full activity feed
Real-time updates on website changes, news, social media posts, ads, and more.